Announced details
Injectable formulations and generic drugs for medical institutions
Combined production capacity for prefilled syringe formulations at the Zao No. 1 Plant and the Zao No. 2 Plant will be approximately 17 million syringes per year
コーアイセイ株式会社 is our consolidated subsidiary
1-7, Zao Matsugaoka 2-chome, Yamagata, Yamagata Prefecture (on the premises of the Zao Plant)
There will be no impact on results for the fiscal year ending June 2026. The impact on results from the following fiscal year onward will be disclosed appropriately.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Injectable formulations with high pharmacological activity, Prefilled syringe products |
| Relationship with the Company | コーアイセイ株式会社 is our consolidated subsidiary |
| Launch date | July 2027 (scheduled start of operations) |
| Applicable area | Injectable formulations and generic drugs for medical institutions |
| Location | 1-7, Zao Matsugaoka 2-chome, Yamagata, Yamagata Prefecture (on the premises of the Zao Plant) |
| Location scale | Building area: 2,793.10 m²; total floor area: 3,419.27 m²; two-story steel-frame structure with ALC panels; production capacity: 12 million syringes per year; liquid preparation capacity: 120 L maximum; water systems: 5 t (WFI) and 4 t (UF) |
| Quantitative Effects | Combined production capacity for prefilled syringe formulations at the Zao No. 1 Plant and the Zao No. 2 Plant will be approximately 17 million syringes per year |
| Impact on Business Performance | There will be no impact on results for the fiscal year ending June 2026. The impact on results from the following fiscal year onward will be disclosed appropriately. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To ensure a stable supply of core products for which demand from medical institutions is high, the company will bring forward the plant's start of operations and establish a framework for further production increases.